2024年度
 肝臓外科学講座
■ 当該年度研究業績数一覧表
研究者名 論文 著書 学会発表 その他
発表
和文英文 和文英文 国内国際














海堀 昌樹   教授
 0 1 0 17  0 0 0 0  0  2  0  0  0  0
松井 康輔   准教授
 0 1 0 2  0 0 0 0  0  1  0  0  0  0
小坂 久   講師
 0 1 0 14  0 0 0 0  1  1  0  0  0  0
山本 栄和   講師
 0 0 1 2  0 0 0 0  0  0  0  0  0  0
木口 剛造   講師
 0 0 0 0  0 0 0 0  0  0  0  0  0  0
石崎 守彦   診療講師
 0 0 0 2  0 0 0 0  0  1  0  0  0  0
松島 英之   診療講師
 0 0 0 2  0 0 0 0  1  1  0  0  0  0
三井 哲史   助教
 0 0 0 0  0 0 0 0  0  0  0  0  0  0
 0 3 1 39  0 0 0 0  2  6  0  0  0  0
■ 学術雑誌
原著
1. 吉田明史、海堀昌樹、藤澤七海、石塚まりこ、住山房央、八田雅彦、小坂久、松井康輔、荏原充宏、関本貢嗣:  がん薬物療法とDrug Delivery System : レンバチニブ内包ナノファイバーシートの開発.  関西医科大学雑誌  75 :1 -5 , 2024
2. Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri
K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A,
Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso
K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M,
Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; Real‐life Practice
Experts for, HCC (RELPEC) Study Group, and, HCC 48 Group (Hepatocellular
Carcinoma Experts from 48 Clinics in Japan).:  Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.  Alimentary pharmacology & therapeutics  60 (10) :1361 -1373 , 2024
3. Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group.:  Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.  Alimentary pharmacology & therapeutics  60 (2) :233 -245 , 2024
4. Yukawa N, Yamada T, Ichikawa D, Aoyama T, Kataoka K, Shioya T, Tamura T,
Shimoyama R, Fukazawa A, Kumamoto K, Yamashita N, Hasegawa S, Saito S, Takemasa
I, Fujita F, Taniai N, Kaibori M, Yoshida H.:  Risk Factors for Adhesive Small Bowel Obstruction After Liver Cancer Surgery.  Cancer diagnosis & prognosis  4 (6) :689 -695 , 2024
5. Ikoma T, Matsumoto T, Boku S, Motoki Y, Kinoshita H, Kosaka H, Kaibori M, Inoue K, Sekimoto M, Fujisawa T, Iwai H, Naganuma M, Tanizaki H, Hisamatsu Y, Okada H, Kurata T.:  Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study.  Cancer immunology, immunotherapy : CII  73 (7) :126 , 2024
6. Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri
K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M,
Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso
K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M,
Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T.:  Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.  Cancer medicine  14 (2) :e70618 , 2025
7. Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Hatanaka T, Tani J, Takaguchi K, Atsukawa M, Itobayashi E, Nishimura T, Tsuji K, Tajiri K, Ishikawa T, Yasuda S, Toyoda H, Fukunishi S, Ogawa C, Kakizaki S, Shimada N, Naganuma A, Kawata K, Kosaka H, Kuroda H, Matono T, Yata Y, Ochi H, Tada F, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T; Representing the Real‐life Practice Experts for HCC Study Group with Hepatocellular Carcinoma experts from 48 clinics in Japan (RELPEC/HCC 48 Group):  Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.  Cancer reports (Hoboken, N.J.)  7 (4) :e2042 , 2024
8. Lai TT, Ishida M, Kosaka H, Matsui K, Matsushima H, Yamamoto H, Kiguchi G,
Nguyen KV, Inoue K, Takada M, Kato H, Hirose Y, Yoshii K, Kaibori M.:  The Prognostic Impact of Adipophilin Expression on Long-Term Survival Following Liver Resection in Patients with Colorectal Liver Metastases.  Cancers  16 (22) :3827 , 2024
9. Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Aoki T, Tanaka K, Tanaka T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).:  Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.  Hepatology Research  54 (4) :382 -391 , 2024
10. Murai K, Hikita H, Kodama T, Kaibori M, Nishimura Y, Tatsumi T, Yamada T, Kanto T, Mochida S, Takehara T.:  The impact of the COVID-19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan - a multicenter collaborative observational study.  Hepatology research  54 (5) :439 -450 , 2024
11. Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K,
Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H,
Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H,
Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F,
Nakamura S, Nakamura Y, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T,
Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H,
Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; RELPEC Group and HCC 48 Group.:  Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.  Hepatology research  55 (3) :444 -453 , 2025
12. Kaibori M, Yoshii K, Lai TT, Matsushima H, Tatsuishi W, Inada R, Matsugu Y,
Komeda K, Asakuma M, Tanaka K, Sato H, Yamada T, Miyasaka T, Hasegawa Y, Matsui
R, Takehara K, Ko S, Yamato I, Washizawa N, Taniguchi H, Kimura Y, Ishibashi N,
Akagi Y, Hiki N, Higuchi T, Shingai T, Kamei T, Okamoto H, Nagakawa Y, Takishita
C, Kohri T, Matsui K, Nabeya Y, Fukatsu K, Miyata G.:  Prospective Survey of Postoperative Pain in Japan: A Multicenter, Observational Study.  Journal of clinical medicine  14 (4) :1130 , 2025
13. Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi
T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma
A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau
KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL.:  Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.  Journal of clinical oncology  42 (34) :4060 -4070 , 2024
14. Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini,M:  Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study.  Liver Cancer(S. Karger)  13 (5) :522 -536 , 2024
15. Shinkawa, H; Kaibori, M; Ueno, M; Yasuda, S; Ikoma, H; Aihara, T; Nakai, T; Kinoshita, M; Kosaka, H; Hayami, S; Matsuo, Y; Morimura, R; Nakajima, T; Nobori, C; Ishizawa, T:  Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study.  Liver Cancer(S. Karger)  14 (1) :80 -91 , 2024
16. Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, Finkelmeier F, Yoo
C, Presa J, Amadeo E, Genovesi V, De Grandis MC, Iavarone M, Marra F, Foschi F,
Tamburini E, Rossari F, Vitiello F, Bartalini L, Soldà C, Tovoli F, Vivaldi C,
Lonardi S, Silletta M, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Himmelsbach V,
Montes M, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama
K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa
T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T,
Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui
A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi
Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Camera S, Foti S,
Aldrighetti L, Cascinu S, Casadei-Gardini A, Piscaglia F.:  Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.  Liver international  44 (5) :1108 -1125 , 2024
17. Promsorn P, Yamaguchi T, Kosaka H, Aoi K, Yoshida K, Matsushima H, Matsui K,
Shimoda S, Kaibori M, Naganuma M.:  Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib.  Molecular and clinical oncology  21 (3) :63 , 2024
18. Van Nguyen, Khanh; Matsui, Kosuke; Kosaka, Hisashi; Matsushima, Hideyuki; Yamamoto, Hidekazu; Lai, Tung Thanh; Inoue, Kyoko; Takada, Moriyasu; Tada, Fujimasa; Hiraoka, Atsushi; Hatanaka, Takeshi; Tada, Toshifumi; Kumada, Takashi; Kato, Hiroki; Yoshii, Kengo; Yamaguchi, Takashi; Shimoda, Shinji; Naganuma, Makoto; Kaibori, Masaki:  Cachexia Index as a Prognostic Indicator in Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy.  Oncology  :Online ahead of print , 2025
19. Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, Ohama H, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Toyoda H, Matono T, Yata Y, Ogawa C, Naganuma A, Tani J, Atsukawa M, Nishimura T, Tajiri K, Kawata K, Kosaka H, Kuroda H, Hirooka M, Nishikawa H, Tada F, Nakamura S, Kanayama Y, Nouso K, Tanaka H, Tanaka K, Imai M,
Tsutsui A, Nagano T, Aoki T, Koshiyama Y, Morishita A, Itokawa N, Okubo T, Arai T, Fukunishi S, Noritake H, Nakamura Y, Yoshida O, Enomoto H, Kaibori M, Hiasa Y, Kumada T; Real-life Practice Experts for HCC.:  The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient.  Oncology.  , 2025
20. Nakamura T, Masuda A, Kako M, Enomoto H, Kaibori M, Fujita Y, Tanizawa K, Ioji T, Fujimori Y, Fukami K, Hazama T, Iwamoto H, Kako Y, Kobayashi K, Koga H, Nagafuji K, Ohtake T, Suzuki H, Takashima T, Tsukiyama T, Uojima H, Yamahara K, Yamakado K, Yamamoto H, Yoh K, Yoshihara S, Kawamoto A, Nishiguchi S, Kobayashi S, Torimura T, Kawaguchi T.:  Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial.  Regenerative Therapy  27 :455 -463 , 2024
21. Nakatake R, Funatsuki T, Koshikawa Y, Okuyama T, Ishizaki M, Takekita Y, Kato
M, Kitade H:  C reactive protein albumin ratio as a new predictor of postoperative delirium after cholecystectomy for acute cholecystitis.  Scientific reports  14 (1) :21704 , 2024
22. Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N,
Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Tanaka H, Nishikawa
H, Shibata H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N,
Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y,
Kumada T.:  Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.  Scientific reports  15 (1) :72 , 2025
23. Kosaka H, Matsui K, Ikeura T, Ito T, Ohe C, Kono Y, Matsushima H, Yamamoto H,
Sekimoto M, Kaibori M.:  Prognostic impact of combination therapy with gemcitabine and cisplatin plus S-1 and subsequent conversion surgery for initially unresectable upper biliary tract cancers.  Surgery today  55 (3) :351 -359 , 2025
24. Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N,
Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A.:  Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.  Targeted oncology  19 (4) :645 -659 , 2024
25. Yamamoto H, Isono K, Honda M, Sugawara Y, Inomata Y, Hibi T.:  Impact of Altered Graft Position During Living Donor Liver Retransplantation and its Outcomes.  Transplantation proceedings  57 (2) :284 -291 , 2025
症例報告
1. Nakatake R, Kitade H, Ishizaki M, Yanagida H, Okuyama T, Uemura Y, Sekimoto M.:  Giant hemorrhagic pancreatic pseudocyst with suspected cystic pancreatic tumor: a case report.  Journal of surgical case reports  2024 (6) :rjae393 , 2024
■ 学会発表
全国規模の学会
1. ◎松島英之, 海堀昌樹, 八田雅彦, 林 美樹夫, 藤堂具紀: 難治性肉腫移植マウスにおける第三世代遺伝子改変単純ヘルペスウイルスの腫瘍抑制効果.  第2回日本ウイルス療法学会,  東京,  2024/11
2. ◎奥山哲矢, 中竹利知, 伊藤健太郎, 石崎守彦, 柳田英佐, 北出浩章, 義澤克彦, 池谷幸信, 西澤幹雄, 里井壯平: Baicaleinはラットにおいて部分肝切除を伴う肝虚血再灌流障害を抑制する.  第47回日本分子生物学会年会,  福岡,  2024/11
3. ◎山口隆志, 青井一憲, 諏訪兼彦, 山科雅央, 吉田勝紀, 山敷宣代, 松島英之, 小坂久, 松井康輔, 海堀昌樹, 下田慎治, 長沼誠: 切除不能肝細胞癌に対する薬物治療をシークエンシャルに行うために必要な肝予備能の検討.  第60回日本肝臓学会総会,  熊本城ホール,  2024/06
4. ◎小坂久, 池浦司, 海堀昌樹: 切除不能胆道癌に対するtripletを中心とした薬物療法とその後のコンバージョン手術の意義.  第60回日本肝臓学会総会,  熊本城ホール,  2024/06